Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to either alone.
Epistemonikos ID: 14bd1f5b55854b22cde90162d6170f57f5d581f6
First added on: May 11, 2024